Establishment of experimental models for Alzheimer's disease research

References

• Waldemar G, Dubois B, Emre M, Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1–26.
   PubMed Web of Science ®Google Scholar
• Forstl H, Kurz A. Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999;249:288–290.
   PubMed Web of Science ®Google Scholar
• Brookmeyer R, Johnson E, Ziegler-Graham K, Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3:186–91.
   PubMed Web of Science ®Google Scholar
• Seeman P, Seeman N. Alzheimer's disease: beta-amyloid plaque formation in human brain. Synapse 2011;65:1289–97.
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184–5.
   PubMed Web of Science ®Google Scholar
• Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007;8:663–72.
   PubMed Web of Science ®Google Scholar
• Finch CE, Stanford CB. Meat-adaptive genes and the evolution of slower aging in humans. Q Rev Biol 2004;79:3–50.
   PubMed Web of Science ®Google Scholar
• Rosen RF, Farberg AS, Gearing M, Tauopathy with paired helical filaments in an aged chimpanzee. J Comp Neurol 2008;509:259–70.
   PubMed Web of Science ®Google Scholar
• Bading JR, Yamada S, Mackic JB, Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target 2002;10:359–68.
   PubMed Web of Science ®Google Scholar
• Sarasa M, Pesini P. Natural non-transgenic animal models for research in Alzheimer's disease. Curr Alzheimer Res 2009;6:171–8.
   PubMed Web of Science ®Google Scholar
• Janecka JE, Miller W, Pringle TH, Molecular and genomic data identify the closest living relative of primates. Science 2007;318:792–4.
   PubMed Web of Science ®Google Scholar
• Yamashita A, Fuchs E, Taira M, Amyloid beta (Abeta) protein- and amyloid precursor protein (APP)-immunoreactive structures in the brains of aged tree shrews. Curr Aging Sci 2010;3:230–8.
   PubMedGoogle Scholar
• Head E, Pop V, Sarsoza F, Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J Alzheimers Dis 2010;20:637–46.
   PubMedGoogle Scholar
• Head E, Pop V, Vasilevko V, A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci 2008;28:3555–66.
   PubMed Web of Science ®Google Scholar
• Siwak CT, Tapp PD, Milgram NW. Effect of age and level of cognitive function on spontaneous and exploratory behaviors in the beagle dog. Learn Mem 2001;8:317–25.
   PubMed Web of Science ®Google Scholar
• Siwak CT, Tapp PD, Head E, Chronic antioxidant and mitochondrial cofactor administration improves discrimination learning in aged but not young dogs. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:461–9.
   PubMedGoogle Scholar
• Landsberg G. Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:471–9.
   PubMed Web of Science ®Google Scholar
• Siwak CT, Gruet P, Woehrle F, Comparison of the effects of adrafinil, propentofylline, and nicergoline on behavior in aged dogs. Am J Vet Res 2000;61:1410–4.
   PubMedGoogle Scholar
• Carrodeguas JA, Rodolosse A, Garza MV, The chick embryo appears as a natural model for research in beta-amyloid precursor protein processing. Neuroscience 2005;134:1285–300.
   PubMedGoogle Scholar
• Gerhardsson L, Lundh T, Minthon L, Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2008;25:508–15.
   PubMed Web of Science ®Google Scholar
• Walton JR. A longitudinal study of rats chronically exposed to aluminum at human dietary levels. Neurosci Lett 2007;412:29–33.
   PubMed Web of Science ®Google Scholar
• Luo Y, Niu F, Sun Z, Altered expression of Abeta metabolism-associated molecules from D-galactose/AlCl(3) induced mouse brain. Mech Ageing Dev 2009;130:248–52.
   PubMed Web of Science ®Google Scholar
• Shuchang H, Qiao N, Piye N, Protective effects of gastrodia elata on aluminium-chloride-induced learning impairments and alterations of amino acid neurotransmitter release in adult rats. Restor Neurol Neurosci 2008;26:467–73.
   PubMedGoogle Scholar
• He X, Zhong ZM, Che Y. [Locomotor activity and learning and memory abilities in Alzheimer's disease induced by Aluminum in an acid environment in Zebrafish]. Dongwuxue Yanjiu 2012;33:231–6.
   PubMedGoogle Scholar
• Hua H, Munter L, Harmeier A, Toxicity of Alzheimer's disease-associated Abeta peptide is ameliorated in a Drosophila model by tight control of zinc and copper availability. Biol Chem 2011;392:919–26.
   PubMedGoogle Scholar
• Andrasi E, Pali N, Molnar Z, Brain aluminum, magnesium and phosphorus contents of control and Alzheimer-diseased patients. J Alzheimers Dis 2005;7:273–84.
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhang J, Liu N, Copper ions influence the toxicity of beta-amyloid(1–42) in a concentration-dependent manner in a Caenorhabditis elegans model of Alzheimer's disease. Sci China Life Sci 2011;54:527–34.
   PubMedGoogle Scholar
• Solomon A, Kivipelto M, Wolozin B, Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009;28:75–80.
   PubMed Web of Science ®Google Scholar
• Sparks DL, Kuo YM, Roher A, Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann N Y Acad Sci 2000;903:335–44.
   PubMed Web of Science ®Google Scholar
• Prasanthi JR, Schrag M, Dasari B, Deferiprone reduces amyloid-beta and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet. J Alzheimers Dis 2012;30:167–82.
   PubMed Web of Science ®Google Scholar
• Cui X, Zuo P, Zhang Q, Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid. J Neurosci Res 2006;84:647–54.
   PubMed Web of Science ®Google Scholar
• Hua X, Lei M, Zhang Y, Long-term D-galactose injection combined with ovariectomy serves as a new rodent model for Alzheimer's disease. Life Sci 2007;80:1897–905.
   PubMed Web of Science ®Google Scholar
• Sun ZZ, Chen ZB, Jiang H, Alteration of Abeta metabolism-related molecules in predementia induced by AlCl3 and D-galactose. Age (Dordr) 2009;31:277–84.
   PubMed Web of Science ®Google Scholar
• El-Amouri SS, Zhu H, Yu J, Neprilysin protects neurons against Abeta peptide toxicity. Brain Res 2007;1152:191–200.
   PubMedGoogle Scholar
• Nitta A, Itoh A, Hasegawa T, beta-Amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 1994;170:63–6.
   PubMed Web of Science ®Google Scholar
• Nobakht M, Hoseini SM, Mortazavi P, Neuropathological changes in brain cortex and hippocampus in a rat model of Alzheimer's disease. Iran Biomed J 2011;15:51–8.
   PubMedGoogle Scholar
• Li W, Wu Y, Min F, A nonhuman primate model of Alzheimer's disease generated by intracranial injection of amyloid-beta42 and thiorphan. Metab Brain Dis 2010;25:277–84.
   PubMed Web of Science ®Google Scholar
• Billings LM, Oddo S, Green KN, Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005;45:675–88.
   PubMed Web of Science ®Google Scholar
• Goate A, Chartier-Harlin MC, Mullan M, Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704–6.
   PubMed Web of Science ®Google Scholar
• Murrell J, Farlow M, Ghetti B, A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991;254:97–9.
   PubMed Web of Science ®Google Scholar
• Mullan M, Crawford F, Axelman K, A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992;1:345–7.
   PubMed Web of Science ®Google Scholar
• Hsiao K, Chapman P, Nilsen S, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99–102.
   PubMed Web of Science ®Google Scholar
• Moechars D, Dewachter I, Lorent K, Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 1999;274:6483–92.
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173–7.
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Rojiani A, Rosenthal A, Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004;24:6144–51.
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916–9.
   PubMed Web of Science ®Google Scholar
• Van Dam D, De Deyn PP. Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol 2011;164:1285–300.
   PubMed Web of Science ®Google Scholar
• Citron M, Westaway D, Xia W, Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997;3:67–72.
   PubMed Web of Science ®Google Scholar
• Chui DH, Tanahashi H, Ozawa K, Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 1999;5:560–4.
   PubMed Web of Science ®Google Scholar
• Duff K, Eckman C, Zehr C, Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710–3.
   PubMed Web of Science ®Google Scholar
• Holcomb L, Gordon MN, McGowan E, Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97–100.
   PubMed Web of Science ®Google Scholar
• Borchelt DR, Ratovitski T, van Lare J, Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997;19:939–45.
   PubMed Web of Science ®Google Scholar
• Tempier A, He J, Zhu S, Quetiapine modulates conditioned anxiety and alternation behavior in Alzheimer's transgenic mice. Curr Alzheimer Res. 2013 Feb;10(2):199–206.
   PubMedGoogle Scholar
• Mei Z, Zhang F, Tao L, Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro. Neurosci Lett 2009;452:90–5.
   PubMed Web of Science ®Google Scholar
• Paris D, Ganey NJ, Laporte V, Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2010;7:17.
   PubMedGoogle Scholar
• Oddo S, Caccamo A, Kitazawa M, Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003;24:1063–70.
   PubMed Web of Science ®Google Scholar
• Perez SE, Nadeem M, Sadleir KR, Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. Int J Physiol Pathophysiol Pharmacol 2012;4:115–27.
   PubMedGoogle Scholar
• Himeno E, Ohyagi Y, Ma L, Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation. Ann Neurol 2011;69:248–56.
   PubMed Web of Science ®Google Scholar
• Peng J, Liang G, Inan S, Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. Neurosci Lett 2012;516:274–9.
   Google Scholar
• Girard LR, Fiedler TJ, Harris TW, WormBook: the online review of Caenorhabditis elegans biology. Nucleic Acids Res 2007;35:D472–5.
   PubMed Web of Science ®Google Scholar
• Link CD. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A 1995;92:9368–72.
   PubMed Web of Science ®Google Scholar
• Fay DS, Fluet A, Johnson CJ, In vivo aggregation of beta-amyloid peptide variants. J Neurochem 1998;71:1616–25.
   PubMed Web of Science ®Google Scholar
• Link CD, Johnson CJ, Fonte V, Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging 2001;22:217–26.
   PubMed Web of Science ®Google Scholar
• Styren SD, Hamilton RL, Styren GC, X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 2000;48:1223–32.
   PubMed Web of Science ®Google Scholar
• Jowett T. Transgenic zebrafish. Methods Mol Biol 1999;97:461–86.
   PubMedGoogle Scholar
• Sager JJ, Bai Q, Burton EA. Transgenic zebrafish models of neurodegenerative diseases. Brain Struct Funct 2010;214:285–302.
   PubMedGoogle Scholar
• Newman M, Verdile G, Martins RN, Zebrafish as a tool in Alzheimer's disease research. Biochim Biophys Acta 2011;1812:346–52.
   PubMed Web of Science ®Google Scholar
• Newman M, Wilson L, Camp E, A zebrafish melanophore model of amyloid beta toxicity. Zebrafish 2010;7:155–9.
   Google Scholar
• Tomasiewicz HG, Flaherty DB, Soria JP, Transgenic zebrafish model of neurodegeneration. J Neurosci Res 2002;70:734–45.
   PubMed Web of Science ®Google Scholar
• Bai Q, Garver JA, Hukriede NA, Generation of a transgenic zebrafish model of Tauopathy using a novel promoter element derived from the zebrafish eno2 gene. Nucleic Acids Res 2007;35:6501–16.
   PubMed Web of Science ®Google Scholar
• Paquet D, Bhat R, Sydow A, A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest 2009;119:1382–95.
   PubMed Web of Science ®Google Scholar
• Jeibmann A, Paulus W. Drosophila melanogaster as a model organism of brain diseases. Int J Mol Sci 2009;10:407–40.
   PubMed Web of Science ®Google Scholar
• Greeve I, Kretzschmar D, Tschape JA, Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci 2004;24:3899–906.
   PubMed Web of Science ®Google Scholar
• Finelli A, Kelkar A, Song HJ, A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster. Mol Cell Neurosci 2004;26:365–75.
   PubMed Web of Science ®Google Scholar
• Crowther DC, Kinghorn KJ, Miranda E, Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 2005;132:123–35.
   PubMed Web of Science ®Google Scholar
• Iijima K, Chiang HC, Hearn SA, Abeta42 mutants with different aggregation profiles induce distinct pathologies in Drosophila. PLoS One 2008;3:e1703.
   PubMedGoogle Scholar
• Shulman JM, Feany MB. Genetic modifiers of tauopathy in Drosophila. Genetics 2003;165:1233–42.
   PubMed Web of Science ®Google Scholar
• Jackson GR, Wiedau-Pazos M, Sang TK, Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002;34:509–19.
   PubMed Web of Science ®Google Scholar
• Virata MJ, Zeller RW. Ascidians: an invertebrate chordate model to study Alzheimer's disease pathogenesis. Dis Model Mech 2010;3:377–85.
   PubMedGoogle Scholar
• Gervais F, Paquette J, Morissette C, Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007;28:537–47.
   PubMed Web of Science ®Google Scholar
• Bharadwaj P, Martins R, Macreadie I. Yeast as a model for studying Alzheimer's disease. FEMS Yeast Res 2010;10:961–9.
   PubMedGoogle Scholar
• Zhang H, Komano H, Fuller RS, Proteolytic processing and secretion of human beta-amyloid precursor protein in yeast. Evidence for a yeast secretase activity. J Biol Chem 1994;269:27799–802.
   PubMedGoogle Scholar
• Le Brocque D, Henry A, Cappai R, Processing of the Alzheimer's disease amyloid precursor protein in Pichia pastoris: immunodetection of alpha-, beta-, and gamma-secretase products. Biochemistry 1998;37:14958–65.
   PubMedGoogle Scholar
• Zhang W, Espinoza D, Hines V, Characterization of beta-amyloid peptide precursor processing by the yeast Yap3 and Mkc7 proteases. Biochim Biophys Acta 1997;1359:110–22.
   PubMedGoogle Scholar
• Luthi U, Schaerer-Brodbeck C, Tanner S, Human beta-secretase activity in yeast detected by a novel cellular growth selection system. Biochim Biophys Acta 2003;1620: 167–78.
   PubMedGoogle Scholar
• Middendorp O, Ortler C, Neumann U, Yeast growth selection system for the identification of cell-active inhibitors of beta-secretase. Biochim Biophys Acta 2004;1674:29–39.
   PubMed Web of Science ®Google Scholar
• Edbauer D, Winkler E, Regula JT, Reconstitution of gamma-secretase activity. Nat Cell Biol 2003;5:486–8.
   PubMed Web of Science ®Google Scholar
• Edbauer D, Kaether C, Steiner H, Co-expression of nicastrin and presenilin rescues a loss of function mutant of APH-1. J Biol Chem 2004;279:37311–15.
   PubMedGoogle Scholar
• Futai E, Yagishita S, Ishiura S. Nicastrin is dispensable for gamma-secretase protease activity in the presence of specific presenilin mutations. J Biol Chem 2009;284:13013–22.
   PubMedGoogle Scholar
• Steiner H, Pesold B, Haass C. An in vivo assay for the identification of target proteases which cleave membrane-associated substrates. FEBS Lett 1999;463:245–9.
   PubMedGoogle Scholar
• Steiner H, Revesz T, Neumann M, A pathogenic presenilin-1 deletion causes abberrant Abeta 42 production in the absence of congophilic amyloid plaques. J Biol Chem 2001;276:7233–9.
   PubMedGoogle Scholar
• Hughes SR, Goyal S, Sun JE, Two-hybrid system as a model to study the interaction of beta-amyloid peptide monomers. Proc Natl Acad Sci U S A 1996;93:2065–70.
   PubMedGoogle Scholar
• Caine J, Sankovich S, Antony H, Alzheimer's Abeta fused to green fluorescent protein induces growth stress and a heat shock response. FEMS Yeast Res 2007;7:1230–6.
   PubMedGoogle Scholar
• Macreadie I, Lotfi-Miri M, Mohotti S, Validation of folate in a convenient yeast assay suited for identification of inhibitors of Alzheimer's amyloid-beta aggregation. J Alzheimers Dis 2008;15:391–6.
   PubMed Web of Science ®Google Scholar
• Vandebroek T, Vanhelmont T, Terwel D, Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein tau expressed in yeast. Biochemistry 2005;44:11466–75.
   PubMedGoogle Scholar
• Vandebroek T, Terwel D, Vanhelmont T, Microtubule binding and clustering of human Tau-4R and Tau-P301L proteins isolated from yeast deficient in orthologues of glycogen synthase kinase-3beta or cdk5. J Biol Chem 2006;281:25388–97.
   PubMedGoogle Scholar
• Bharadwaj P, Waddington L, Varghese J, A new method to measure cellular toxicity of non-fibrillar and fibrillar Alzheimer's Abeta using yeast. J Alzheimers Dis 2008;13:147–50.
   PubMed Web of Science ®Google Scholar
• Gotz J, Streffer JR, David D, Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry 2004;9:664–83.
   PubMed Web of Science ®Google Scholar
• Duff K, Suleman F. Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? Brief Funct Genomic Proteomic 2004;3:47–59.
   PubMedGoogle Scholar
• Yamashita A, Fuchs E, Taira M, Somatostatin-immunoreactive senile plaque-like structures in the frontal cortex and nucleus accumbens of aged tree shrews and Japanese macaques. J Med Primatol 2012;41:147–57.
   PubMedGoogle Scholar